Literature DB >> 19455642

The MTHFR 677C-->T polymorphism and behaviors in children with autism: exploratory genotype-phenotype correlations.

Robin P Goin-Kochel1, Anne E Porter, Sarika U Peters, Marwan Shinawi, Trilochan Sahoo, Arthur L Beaudet.   

Abstract

New evidence suggests that autism may be associated with (a) varied behavioral responses to folate therapy and (b) metabolic anomalies, including those in folate metabolism, that contribute to hypomethylation of DNA. We hypothesized that children with autism who are homozygous for the MTHFR 677 T allele (TT) and, to a lesser extent those with the CT variant, would exhibit more behavioral problems and/or more severe problematic behaviors than homozygous wild-type (CC) individuals because of difficulties in effectively converting 5,10-MTHF to 5-MTHF. Data from the Autism Genetic Resource Exchange (AGRE) collection were analyzed for all children who met strict criteria for autism per the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule (ADOS) and who had been genotyped for the 677 C to T MTHFR polymorphism (n=147). Chi-square tests, logistic regression, and one-way ANOVAs were used to determine whether differences existed among MTHFR genotypes for specific behaviors on the ADI-R and indices for level of functioning. Exploratory results indicated four behaviors from the ADI-R that were more common and problematic (95% CI) among those with at least one copy of the T allele as compared to homozygous wild-type individuals: direct gaze, current complex body movements, a history of self-injurious behavior, and current overactivity (ORs=2.72, 2.33, 2.12, 2.47, respectively). No differences existed among genotypes for level of functioning as measured with the Peabody Picture Vocabulary Test-Third Edition, Ravens Colored Progressive Matrices, or the Vineland Adaptive Behavior Scales. Findings call for further investigation of the relationship between folate metabolism and problem behaviors among children with autism.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19455642     DOI: 10.1002/aur.70

Source DB:  PubMed          Journal:  Autism Res        ISSN: 1939-3806            Impact factor:   5.216


  19 in total

1.  Gender-specific effect of Mthfr genotype and neonatal vigabatrin interaction on synaptic proteins in mouse cortex.

Authors:  Elinor Blumkin; Tamar Levav-Rabkin; Osnat Melamed; Dalia Galron; Hava M Golan
Journal:  Neuropsychopharmacology       Date:  2011-04-13       Impact factor: 7.853

Review 2.  The Putative Role of Environmental Mercury in the Pathogenesis and Pathophysiology of Autism Spectrum Disorders and Subtypes.

Authors:  G Morris; B K Puri; R E Frye; M Maes
Journal:  Mol Neurobiol       Date:  2017-07-22       Impact factor: 5.590

3.  MTHFR 677T is a strong determinant of the degree of hearing loss among Polish males with postlingual sensorineural hearing impairment.

Authors:  Agnieszka Pollak; Malgorzata Mueller-Malesinska; Urszula Lechowicz; Agata Skorka; Lech Korniszewski; Agnieszka Sobczyk-Kopciol; Anna Waskiewicz; Grazyna Broda; Katarzyna Iwanicka-Pronicka; Monika Oldak; Henryk Skarzynski; Rafał Płoski
Journal:  DNA Cell Biol       Date:  2012-03-16       Impact factor: 3.311

Review 4.  Genetic and epigenomic footprints of folate.

Authors:  J Michael Salbaum; Claudia Kappen
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

5.  How Is CYP17A1 Activity Altered in Autism? A Pilot Study to Identify Potential Pharmacological Targets.

Authors:  Benedikt Andreas Gasser; Johann Kurz; Bernhard Dick; Markus Georg Mohaupt
Journal:  Life (Basel)       Date:  2022-06-10

Review 6.  Oxidative Stress in Autism Spectrum Disorder.

Authors:  Geir Bjørklund; Nagwa A Meguid; Mona A El-Bana; Alexey A Tinkov; Khaled Saad; Maryam Dadar; Maha Hemimi; Anatoly V Skalny; Božena Hosnedlová; Rene Kizek; Joško Osredkar; Mauricio A Urbina; Teja Fabjan; Amira A El-Houfey; Joanna Kałużna-Czaplińska; Paulina Gątarek; Salvatore Chirumbolo
Journal:  Mol Neurobiol       Date:  2020-02-05       Impact factor: 5.590

7.  Cerebral folate receptor autoantibodies in autism spectrum disorder.

Authors:  R E Frye; J M Sequeira; E V Quadros; S J James; D A Rossignol
Journal:  Mol Psychiatry       Date:  2012-01-10       Impact factor: 15.992

Review 8.  A review of traditional and novel treatments for seizures in autism spectrum disorder: findings from a systematic review and expert panel.

Authors:  Richard E Frye; Daniel Rossignol; Manuel F Casanova; Gregory L Brown; Victoria Martin; Stephen Edelson; Robert Coben; Jeffrey Lewine; John C Slattery; Chrystal Lau; Paul Hardy; S Hossein Fatemi; Timothy D Folsom; Derrick Macfabe; James B Adams
Journal:  Front Public Health       Date:  2013-09-13

Review 9.  Evidence linking oxidative stress, mitochondrial dysfunction, and inflammation in the brain of individuals with autism.

Authors:  Daniel A Rossignol; Richard E Frye
Journal:  Front Physiol       Date:  2014-04-22       Impact factor: 4.566

Review 10.  Treatments for biomedical abnormalities associated with autism spectrum disorder.

Authors:  Richard Eugene Frye; Daniel A Rossignol
Journal:  Front Pediatr       Date:  2014-06-27       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.